HIV

Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries. The company has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, the Hyderabad-based drug maker said in a statement. Lenacapavir is a US Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus a type 1 (HIV-1) infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally. Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the US and Europe markets in the year 2022. As per the agreement, Dr Reddy's w

Zydus Lifesciences on Friday said it has received approval from the US health regulator to market a generic antiviral medication used in the treatment of HIV-1 infection. The company has received final approval from the US Food and Drug Administration (USFDA) for Darunavir Tablets, the company said in a statement. Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body. It is indicated for the treatment of HIV-1 infection in adult patients. It is also indicated for the treatment of HIV-1 infection in pediatric patients three years of age and older. It must be co-administered with Ritonavir and with other antiretroviral agents. Zydus said the product will be manufactured at the group's formulation manufacturing facility in SEZ, Ahmedabad, Gujarat. As per IQVIA MAT data, Darunavir tablets (75 mg, 150 mg, 600 mg, and 800 mg) had annual sales of USD 275 million in the US. Shares of the company were trading

Nagaland, which has more than 12,000 people living with HIV (PLHIV) on Monday got its first HIV-1 viral load laboratory. The laboratory set up in Naga Hospital Authority Kohima (NHAK) will help the patients undergo viral load testing, which is required at least once a year for PLHIV. Commissioner and Secretary for Health and Family Welfare Department, Y Kikheto Sema, said that India, being a signatory of the United Nations Sustainable Development Goal 3.3, is committed to ending AIDS epidemic as a public health threat by 2030. "Nagaland has approximately 12,290 PLHIV who are on treatment and many more are unreached and untested for HIV. The state has the second-highest HIV positive cases in the country. "PLHIV have to mandatorily undergo viral load testing at least once a year. If the viral load does not come down, it indicates that the person is not responding to the drug and therefore will need another line of treatment. The laboratory will help doctors provide correct treatment

INVEX Health is soon set to launch India's first oral HIV self-test, the company announced on Tuesday

Heart diseases contributed 28.1% of the total deaths in India, in 2016 compared to 15.2% in 1990

Pharmaceutical firm Lupin on Monday said it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection. The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in a regulatory filing. The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.

The government is providing free lifelong antiretroviral medicines for people living with HIV under its National AIDS Control Programme, Union Minister of State for Health Bharti Pravin Pawar said

Three doses of HEPLISAV-B vaccine provide full protection to adults with HIV, who were never immunised against hepatitis B virus (HBV) either through vaccination or infection, according to a study. In the research presented at the annual IDWeek conference held in Washington, US from October 19 to 23, the researchers from University of Cincinnati and Cornell University tested the three-dose course of HEPLISAV-B among 68 adults living with HIV at 38 sites in the US, South Africa, and Thailand. None of the participants had either received a previous HBV vaccination or had evidence of a previous HBV infection - all were on antiretroviral therapy to combat infection by retroviruses such as HIV. Retroviruses are a group of viruses that contain two single-strand linear RNA molecules per virion, or a viral particle, and reverse transcriptase (RNA to DNA). Following the initial dose of HEPLISAV-B vaccine 0.5 milliliter (mL) as an intramuscular injection, the study participants received ...

Drug firm Lupin on Tuesday said it has received an approval from the US health regulator to market Darunavir Tablets, used to treat Human Immunodeficiency Virus (HIV) infection, in the American market. The Mumbai-based company said it is the exclusive first filer for 800 mg tablets and is eligible for 180-day exclusivity. Lupin will also potentially have shared 180-day exclusivity on the 600 mg tablets, it added. The company has received the approval from the US Food and Drug Administration (USFDA) for the medication in strengths of 600 mg and 800 mg, Lupin said. The drug firm's product is a generic equivalent of Janssen Products' Prezista Tablets. As per MAT June 2022 data, Darunavir tablets (600 mg and 800 mg) had estimated annual sales of USD 343 million in the US. Lupin shares were trading 2.17 per cent up at Rs 738.30 apiece on the BSE.

Medicines to treat diabetes, HIV, TB, contraceptives, hormonal medicines included in National List of Essential Medicines

Health Canada approved the request by Canadian Blood Services to end the policy that restricts homosexuals from donating blood for three months after engaging in gay sex

French researcher Luc Montagnier, who won a Nobel Prize in 2008 for discovering the HIV virus and more recently spread false claims about the coronavirus, has died at age 89, according to officials

Sustainability and development have been key goals for the group

The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad

The product will be manufactured at the company's facility in Nagpur

Company plans to produce its jab at eight sites, including Serum Institute

The Haryana government will bring patients of the state suffering from cancer, HIV and serious kidney ailments under the ambit of its social security pension scheme.

The woes of MBBS students on Covid duty, many families continue to struggle for food and jobs, and lessons in living from the ocean-news relevant to India's fight against Covid-19

Approximately once every minute and 40 seconds, a child or young person under the age of 20 was infected with HIV last year, the UN Children's Fund (UNICEF) said on Wednesday

In a major study, researchers have identified the important factors which could be contributing to the chronic inflammation in people living with HIV.